The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Trial of PDL192 in Subjects With Advanced Solid Tumors
Official Title: A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors
Study ID: NCT00738764
Brief Summary: This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
Detailed Description: The primary study objective is to determine the maximum tolerated dose of PDL192 in subjects with advanced solid tumors.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Site Reference ID/Investigator# 53365, Scottsdale, Arizona, United States
Site Reference ID/Investigator# 53364, Aurora, Colorado, United States
Name: Mihail Obrocea, MD
Affiliation: Abbott Biotherapeutics Corp.
Role: STUDY_DIRECTOR